Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (MS), according to an editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a Phase 2 clinical trial following successful completion of Phase 1 safety studies and key toxicology programs.

The editorial highlighted more than a decade of preclinical research supporting Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated and chronic inflammatory disease treatment markets.

This advancement is significant because it addresses a fundamental gap in MS treatment: protecting the myelin sheath directly, rather than solely modulating the immune system. If successful, Lucid-MS could offer a new therapeutic approach for patients who do not respond adequately to existing immunomodulatory drugs. The collaboration with Massachusetts General Hospital on PET imaging further enhances the potential to monitor remyelination in real time, a capability that could accelerate clinical development and provide objective endpoints for Phase 2 trials.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

For more details, the full press release is available at https://ibn.fm/6ylQf. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.